Tier 3 — preclinical
Sirt6 promotes tumor growth and suppresses immune surveillance
Cancer Cell International
2026
26(1):20
Bibliography
- PubMed
- PMID 41530841
- PubMed Central
- PMC12809971
- Funding
- Funded by the Huanghai University Scientific Research Foundation, Shandong Provincial Key R&D Program (2023CXPT040), and Science and Technology Projects in Qingdao West Coast New District (2021-3).
- Competing interests
- The authors declared no competing interests.
Study snapshot
| Design | Preclinical tumor-bearing mouse study testing the SIRT6 activator UBCS039 with immune and tumor-growth readouts. |
|---|---|
| Model | BALB/c-nude mice implanted with multiple human tumor-derived cell lines. |
| Sample | 60 five-week-old female BALB/c nude mice were randomized to UBCS039, DMSO or PBS pretreatment groups (20 per group); tumor-cell-line experiments used 5 mice per subgroup and were repeated three times. |
| Intervention | UBCS039 pretreatment versus vehicle controls. |
| Duration | Tumor-model dependent. |
| Endpoints | Tumor growth; GM-CSF; IL-10; adenosine; NK-cell measures; IFN-gamma; tumor-associated immune polarization |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- SIRT6 and Cancer: Tumor Suppression, Activation Risks & Conflicting EvidenceSIRT6 can suppress tumors in some models yet support growth in others. Review MDL-800, UBCS039, cancer metabolism, immune surveillance and what human...Read analysis
- SIRT6 Activator Side Effects: Fucoidan, Forvisirvat & Long-Term RisksSIRT6 activator side effects and safety: fucoidan tolerance, bleeding concerns, pregnancy, medications, long-term uncertainty and synthetic activator trial data.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
